The underlying cause of LCHADD retinopathy is not fully understood. This presentation will look at the research that identifies the cell in the eye that is initially affected and characteristics associated with vision loss. Join Dr. Gillingham as she discusses early data on the natural history study and some new pre-clinical models to test novel treatments for LCHADD retinopathy.
What is "the Mito Cocktail"? Referring to the combination of vitamins and supplements used as therapies in the treatment and management of mitochondrial disease...
Dr. Michio Hirano, Chief of the Neuromuscular Division at Columbia University Medical Center, and Kris Engelstad MS CGC, a board-certified genetic counselor and program...
Join Marcelle Longlade; yoga teacher, chronic condition advocate, biomedical engineer, and devoted entrepreneur for a chair yoga session and discussion about relieving some stress...
